Skip to content

Feasibility study of planned neck dissection based on tumor HPV status in advanced oropharyngeal carcinoma receiving concurrent chemoradiotherapy

Feasibility study of planned neck dissection based on tumor HPV status in advanced oropharyngeal carcinoma receiving concurrent chemoradiotherapy - Planned neck dissection in HPV-negative advanced oropharyngeal carcinoma receiving concurrent chemoradiotherapy

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000018108
Enrollment
60
Registered
2015-06-29
Start date
2015-06-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oropharyngeal carcinoma

Interventions

HPV infection(+): planed neck dissection(-) HPV infection(-): planed neck dissection(+)

Sponsors

Department of otorhinolaryngology, head and neck surgery,Graduate school of medicine, university of the Ryukyus.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The advanced oropharyngeal cancer patient determined by histopathological or cytologic examination, and has multiple neck lymph metastasis (N2b,N2c,and N3 stage). 2. The patient who agree with detecting HPV infection by p16 immunostaining, the HPV DNA in situ hybridization method, the PCR method. 3. The patient who have a measurable lesion or an evaluable lesion by RECIST. 4. Patient's age is older than 20 years old or younger than 80 years old. 5. The patient who accomplished concurrent chemoradiotherapy as primary treatment. 6. Performance status(ECOG) is 0 or 1. 7. The patient that the function of the main organ (heart, the lungs, the liver, kidney, marrow) maintained normal.

Exclusion criteria

Exclusion criteria: 1. The patient who has severe complications. 2. The patient who has distant metastasis to other organs. 3. The patient who has treated by the radiation therapy to the irradiation part concerned. 4. The patient who have severe drug allergy. 5. The patient who have multiple primary cancer which is impossible to control except head and neck cancer. 6. The woman who has been pregnant or possiblity of pregnancy. 7. The patient who was judged inappropriate target by chief doctor or other doctors concerned with this study.

Design outcomes

Primary

MeasureTime frame
neck lymph node recurrence cumulative incidence rate

Secondary

MeasureTime frame
overall survival disease specific survival rate recurrent free survival rate

Countries

Japan

Contacts

Public ContactHidetoshi Kinjou

University of Ryukyus hospital Department of otorhiolaryngology, head and neck surgery

h111853@med.u-ryukyu.ac.jp098-895-1183

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026